Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds independent research and education advancing science and patient care in cystic fibrosis, pain, beta thalassemia, sickle cell disease, and IgA nephropathy.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | 2026 (next cycle for VIA, RIA, Circle of Care awards)
Funding Amounts: No set cap for general grants/ISS; typical awards: up to $750,000 over 3 years (RIA, VIA); up to $125,000 over 2 years (Mentored RIA); multi-year requests possible.
Summary: Funding for independent research, education, and sponsorships advancing care and knowledge in cystic fibrosis and other Vertex-aligned serious diseases.
Key Information: Requests must align with Vertex's disease areas of interest and be submitted at least 60 days before activity start.
Description
Vertex Pharmaceuticals offers a broad portfolio of external funding opportunities to support independent research, education, and community initiatives in areas aligned with its scientific and clinical interests—primarily cystic fibrosis, pain (US only), beta thalassemia, sickle cell disease, and IgA nephropathy. Funding is available through investigator-sponsored studies (ISS), independent medical education (IME), patient education and advocacy programs, and sponsorships of scientific meetings or events. The program is designed to foster scientific progress and improve patient outcomes by supporting projects that advance knowledge, address unmet needs, and encourage innovation.
